Axsome Therapeutics, Inc.

NASDAQ:AXSM

Biotechnology

Healthcare
$134.00 +0.10%

+$0.25 today

Market cap
$7.05B
Beta
0.60
P/E (TTM)
-68.6
EPS (TTM)
-$3.68
52W Low $96.09High $257.93

Volume 0.74M

Average 0.72M

AXSM Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Axsome Therapeutics, Inc.NASDAQ: AXSM

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 51.5M shares rose 4.2% year over year, in line with the +4.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +7.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +4.2% toward the trailing-twelve-month pace of +4.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
51.5M+0.6% QoQ
Last fiscal yearDec 2025
49.75M+3.8% YoY
LTMJun 2026
50.84M+4.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.2%——
1 year+3.8%——
3-year CAGR+7.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
49.75M USD
Year-over-year change
+3.8%
4-year CAGR
+7.2%

Weighted Avg Shares (Diluted) vs competitors

How AXSM compares with its peers on the latest reported figures

  • AXSM's LTM Jun 2026 weighted avg shares (diluted) of 50.84M shares is the 9th highest of the 11 companies compared; the peer median is 88.92M shares.
  • Its year-over-year change of +4.3% is the 7th highest of 11, against a peer median of +6.1%.
  • Over three fiscal years its annual growth of +7.0% compares with a peer median of +6.4%.
AXSM Competitors Peer median
Weighted Avg Shares (Diluted) for AXSM and competitors
Company Period LTM YoY 3-year CAGR
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026111.54M +30.4%+42.5%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026103.83M +1.6%+1.2%
XENEXenon Pharmaceuticals Inc.LTM Sep 202691.49M +16.1%+9.4%
AVXLAnavex Life Sciences Corp.LTM Dec 202586.34M +2.9%+3.5%
JAZZJazz Pharmaceuticals plcLTM Sep 202665.3M +6.5%-0.8%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.4M +2.1%-2.9%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
Peer median (excluding AXSM) 88.92M+6.1%+6.4%

Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050.04M270.6M385.69M638.5M
Cost of Revenue05.2M26.07M33.3M47.48M
Gross Profit044.84M244.54M352.39M591.02M
Gross Margin—89.6%90.4%91.4%92.6%
Research & Development58.06M57.95M97.94M187.08M183.28M
Selling, General & Admin66.65M159.25M323.12M411.36M570.6M
Operating Expenses124.71M224.64M476.36M632.95M760.25M
Depreciation & Amortization76K4.4M6.83M7.96M9.06M
EBITDA(124.63M)(175.4M)(224.99M)(272.6M)(168.08M)
EBITDA Margin—-350.5%-83.1%-70.7%-26.3%
Operating Income(124.71M)(179.8M)(231.83M)(280.56M)(169.24M)
Operating Margin—-359.3%-85.7%-72.7%-26.5%
Interest Income00009.37M
Interest Expense5.7M7.34M6.45M6.57M6.56M
Other Income / Expenses(5.7M)(7.34M)(6.45M)(6.57M)(14.47M)
Income Before Tax(130.4M)(187.13M)(238.28M)(287.13M)(183.7M)
Pre-Tax Margin—-374.0%-88.1%-74.4%-28.8%
Income Tax Expense00960K85K(530K)
Net Income(130.4M)(187.13M)(239.24M)(287.22M)(183.17M)
Net Margin—-374.0%-88.4%-74.5%-28.7%
EPS (Basic)(3.47)(4.60)(5.27)(5.99)(3.68)
EPS (Diluted)(3.47)(4.60)(5.27)(5.99)(3.68)
Weighted Avg Shares37.62M40.66M45.43M47.91M49.75M
Weighted Avg Shares (Diluted)37.62M40.66M45.43M47.91M49.75M

Axsome Therapeutics, Inc.

NASDAQ:AXSM

Intrinsic Alpha fair value

Locked

Current Price

$134.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.